Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
New England Research Institutes The Spinal Muscular Atrophy Foundation |
---|---|
Information provided by: | New England Research Institutes |
ClinicalTrials.gov Identifier: | NCT00756821 |
The goal of this pilot study is to identify a marker or panel of markers in the blood or urine from a wide range of Spinal Muscular Atrophy (SMA) patients that segregates with measures of clinical severity. From this identification of candidate biomarkers, it is hoped that further investigations, both longitudinal natural history and clinical efficacy studies, will verify a biomarker with the sensitivity and specificity that will allow its eventual use as a validated pharmacodynamic marker or surrogate endpoint. In addition, this effort may elucidate biological pathways that may be potential therapeutic targets.
Condition |
---|
Spinal Muscular Atrophy |
Study Type: | Observational |
Study Design: | Cohort, Cross-Sectional |
Official Title: | A Pilot Study of Biomarkers for Spinal Muscular Atrophy |
Whole blood, plasma, PBMCs, and urine
Enrollment: | 130 |
Study Start Date: | October 2008 |
Study Completion Date: | March 2009 |
Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
SMA cohort
Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
|
Control cohort
Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
|
Spinal Muscular Atrophy (SMA) is one of the two most common inherited children's neuromuscular disorders. There currently is no cure and no therapeutics approved to slow progression of the disease. SMA is characterized by a loss of alpha motor neurons in the spinal cord, severe atrophy of proximal muscles and progressive debility and disability due to respiratory, gastrointestinal and functional complications of the disease.
Although SMA is a relatively common orphan disease, recruitment of patients for the number of candidate therapies is expected to become rate-limiting for the development of therapeutics.
STUDY OBJECTIVES
Primary:
Secondary:
Ages Eligible for Study: | 2 Years to 12 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Children's Hospitals Unviersity Hospitals
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35233 | |
United States, California | |
Stanford University | |
Stanford, California, United States, 94305 | |
United States, Colorado | |
The Children's Hospital | |
Aurora, Colorado, United States, 80045 | |
United States, Iowa | |
University of Iowa | |
Iowa City, Iowa, United States, 52242 | |
United States, Maryland | |
Johns Hopkins Hospital | |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Children's Hospital Boston | |
Boston, Massachusetts, United States, 02115 | |
United States, Michigan | |
Children's Hospital of Michigan, Detroit | |
Detroit, Michigan, United States, 48201 | |
United States, Minnesota | |
Mayo Clinic Rochester | |
Rochester, Minnesota, United States, 55905 | |
United States, Missouri | |
Washington University Medical School | |
St. Louis, Missouri, United States, 63110 | |
United States, New York | |
Columbia University SMA Clinical Research Center | |
New York, New York, United States, 10032 | |
United States, Ohio | |
Cincinnati Children's Hospital Medical Center | |
Cincinnati, Ohio, United States, 45229 | |
The Ohio State University | |
Columbus, Ohio, United States, 43210 | |
United States, Pennsylvania | |
The Children's Hospital of Philadelphia | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Texas | |
Children's Medical Center - Dallas | |
Dallas, Texas, United States, 75207 | |
United States, Utah | |
University of Utah | |
Salt lake City, Utah, United States, 84132 | |
United States, Wisconsin | |
University of Wisconsin Hospital and Clinics | |
Madison, Wisconsin, United States, 53792 | |
Canada, Ontario | |
The Hospital for Sick Children | |
Toronto, Ontario, Canada, M5G 1X8 | |
Children's Hospital - London Health Sciences Center | |
London, Ontario, Canada, N6A 2E3 |
Principal Investigator: | Richard Finkel, MD | Children's Hospital of Philadelphia |
Principal Investigator: | Thomas Crawford, MD | Johns Hopkins University |
Principal Investigator: | Petra Kaufmann, MD | Columbia University |
Responsible Party: | The Spinal Muscular Atrophy Foundation ( The Spinal Muscular Atrophy Foundation ) |
Study ID Numbers: | BforSMA |
Study First Received: | September 18, 2008 |
Last Updated: | March 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00756821 History of Changes |
Health Authority: | United States: Institutional Review Board |
Spinal Muscular Atrophy Blood Biomarkers Urine Biomarkers Type I Spinal Muscular Atrophy Type II Spinal Muscular Atrophy |
Type III Spinal Muscular Atrophy Modified Hammersmith Functional Motor Scale Disease severity Biomarkers |
Pathological Conditions, Anatomical Spinal Cord Diseases Spinal Muscular Atrophy Central Nervous System Diseases Neurodegenerative Diseases Signs and Symptoms Werdnig-Hoffmann Disease Neuromuscular Diseases |
Muscular Atrophy, Spinal Neurologic Manifestations Atrophy Degenerative Motor System Disease Motor Neuron Disease Muscular Atrophy Progressive Spinal Muscular Atrophy |
Pathological Conditions, Anatomical Neuromuscular Manifestations Spinal Cord Diseases Nervous System Diseases Central Nervous System Diseases Neurodegenerative Diseases Signs and Symptoms |
Neuromuscular Diseases Muscular Atrophy, Spinal Neurologic Manifestations Atrophy Motor Neuron Disease Muscular Atrophy |